Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences The RNA Summit: Research, Diagnostics & Therapeutics

Frank Slack's Biography

Frank Slack, Director, Institute for RNA Medicine, Beth Israel Deaconess Medical Center Cancer Center/Harvard Medical School

Frank Slack received his B.Sc. from the University of Cape Town in South Africa, before completing his Ph.D. in molecular biology at Tufts University School of Medicine. He started work on microRNAs as a postdoctoral fellow in Gary Ruvkun’s laboratory at Harvard Medical School, where he co-discovered the second known microRNA, let-7. He is currently Director, Institute of RNA Medicine at the Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School in Boston, MA. Professor Slack has pioneered various aspects of the microRNA field and continues to make important contributions to this aspect of post-transcriptional control of gene regulation in stem cell development, cancer and aging. For example Professor Slack and colleagues were co-discoverers of the second known microRNA, let-7 (Reinhart et al Nature, 2000), and the co-discoverers of the first known human microRNA (Pasquinelli et al. Nature, 2000).

Frank Slack Image

MicroRNA-based Therapeutics In Cancer

Monday, 13 November 2017 at 09:00

Add to Calendar ▼2017-11-13 09:00:002017-11-13 10:00:00Europe/LondonMicroRNA-based Therapeutics In CancerThe RNA Summit: Research, Diagnostics and Therapeutics in Boston, USABoston,

MicroRNAs are small non-coding RNAs that regulate gene expression to control important aspects of development and metabolism such as cell differentiation, apoptosis and lifespan. miR-21, miR-155, let-7 and miR-34 are microRNAs implicated in human cancer. Specifically, human let-7 and miR-34 are poorly expressed or deleted in lung cancer, and over-expression of let-7 or miR-34 in lung cancer cells inhibits their growth, demonstrating a role for these miRNAs as tumor suppressors in lung tissue. let-7 and miR-34 regulate the expression of important oncogenes implicated in lung cancer, suggesting a mechanism for their involvement in cancer. We are focused on the role of these genes in regulating proto-oncogene expression during development and cancer, and on using miRNAs to suppress tumorigenesis. In contrast, miR-21 and miR-155 are oncomiRs and up-regulated in many cancer types. We are also developing effective strategies to target these miRNAs as a novel anti-cancer approach. Lastly we are examining the non-coding portions of the genome for mutations and variants that are likely to impact the cancer phenotype. We have successfully resequenced the 3’UTRome and microRNAome from cancer patients with a family history of cancer.

Add to Calendar ▼2017-11-13 00:00:002017-11-14 00:00:00Europe/LondonThe RNA Summit: Research, Diagnostics and TherapeuticsThe RNA Summit: Research, Diagnostics and Therapeutics in Boston, USABoston,